|
Number of cancer cases among subjects that subsequently became digitoxin users. |
|||||
| ICD-10 |
Site |
Sex |
Digitoxin group |
Control group |
Odds Ratio (95% CI) |
|
|
|||||
| C50 |
Breast |
F |
275 |
232 |
1.19(1.11, 1.28) |
| C61 |
Prostate |
M |
370 |
296 |
1.25(1.08, 1.45) |
| C18–21 |
Colo-rectal |
M+F |
430 |
325 |
1.32(1.15, 1.52) |
| C32–34 |
Lung |
M+F |
163 |
112 |
1.46(1.15, 1.86) |
| C64,C65,C67,C68 |
Kidney, urinary |
M+F |
201 |
180 |
1.06(0.95, 1.17) |
| C43.C44 |
Melanoma, other skin |
M+F |
154 |
191 |
0.81 (0.66, 0.99) |
| C81–C85,C88– |
Leukemia/Lymphoma |
M+F |
198 |
117 |
1.69(1.35,2.11) |
| C92 |
|||||
| C00–C97 |
All sites |
M+F |
2435 |
2017 |
1.21 (1.15, 1.28) |
|
Number of cancer cases among subjects that subsequently became digitoxin users,and among matched controls.Digitoxin group=the cancer cases among the 9271 patients constituting the database just before the start on digitoxin medication. Control group=for each subject in the digitoxin group one control was randomly picked out from the general population. These controls were matched on birthday and gender and should be alive at the time when the corresponding digitoxin user started on digitoxin. | |||||
Haux et al. BMC Cancer 2001 1:11 doi:10.1186/1471-2407-1-11 |
|||||